AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00250926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
Study NCT00854750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR
Description: SQ weekly injection
Study NCT04252144 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dietary assessment
Description: Dietary assessment is not within standards of care for patients with gastroesophageal reflux disease in Russia. Subjects enrolled to the study are to be interviewed on most common foods consumption in terms of frequency of use and sizes of portions.
Study NCT04252144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dietary assessment
Description: Dietary assessment is not within standards of care for patients with gastroesophageal reflux disease in Russia. Subjects enrolled to the study are to be interviewed on most common foods consumption in terms of frequency of use and sizes of portions.
Study NCT04524884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day.
Study NCT04524884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
Study NCT03444753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986299
Description: Specified dose on specified day
Study NCT03444753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day
Study NCT03444753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified day
Study NCT00354458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofylline
Description: rolofylline 30 mg IV QD; 3 days
Study NCT00354458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: rolofylline Pbo 30 mg IV QD; 3 days
Study NCT03075007 — intervention group
Intervention type: RADIATION
Intervention: Florbetaben F18
Description: 10Meq of Florbetaben F 18 via intravenous injection is to be used. Visit duration is approximately 3 hours.
Study NCT03075007 — intervention group
Intervention type: PROCEDURE
Intervention: Transcranial Doppler
Description: All participants will undergo Doppler ultrasonography that measures the velocity of blood flow through the brain's blood vessels. Visit duration is approximately 45 minutes and will be scheduled for either the same day or another day as the PET scan.
Study NCT02088346 — intervention group
Intervention type: OTHER
Intervention: Telemedicine consultation system
Description: Telemedicine consultation system based on portable hardwares
Study NCT02386709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG PET
Description: FDG PET1 before neoadjuvant chemotherapy FDG PET2 after one cycle of neoadjuvant chemotherapy
Study NCT01360060 — intervention group
Intervention type: DRUG
Intervention: Magnesium Sulphate
Description: Magnesium sulphate was infused for the management of preeclampsia at perioperative period.
Study NCT04217928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Debridement
Description: Arthroscopic debridement will be performed under portal site local anaesthesia.
Study NCT04217928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Hemi-Trapeziectomy with Mini TightRope
Description: Anaesthesia, position and arthroscopy will be performed in the same way as for arthroscopic debridement, except the distal part of the trapezium will be resected to a depth of 3-4mm together with protruding osteophytes.
Study NCT02147353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinecatechins 15% Ointment
Description: Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).
Study NCT02147353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy alone
Description: Cryotherapy will be standardized in all subjects and for all treated lesions.
Study NCT02147353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy alone
Description: Cryotherapy will be standardized in all subjects and for all treated lesions.
Study NCT01759368 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring assisted self-care
Description: Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring
Study NCT02145247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: 3. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~4. Blood samples will be obtained at T = -0.5, 0, and +24 hours.
Study NCT02789527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenotyping
Description: finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam
Study NCT02789527 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: DNA sampling from a saliva sample
Study NCT00899548 — intervention group
Intervention type: GENETIC
Intervention: DNA methylation analysis
Description: laboratory analysis
Study NCT03997188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepilor
Description: ZLC oral suspension and placebo were both started on Day 1 of RT-HeT and ended when RT was completed or at the onset of dysphagia.
Study NCT03997188 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hepilor
Description: ZLC oral suspension and placebo were both started on Day 1 of RT-HeT and ended when RT was completed or at the onset of dysphagia.
Study NCT03513159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathfinder support
Description: A pathfinder will support the patient with structured activities.
Study NCT00631072 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: INKT
Description: Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
Study NCT00631072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF
Description: Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
Study NCT00899548 — intervention group
Intervention type: GENETIC
Intervention: microarray analysis
Description: laboratory analysis
Study NCT00899548 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: laboratory analysis
Study NCT00089752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) Treatment
Description: CPAP device used at night
Study NCT00089752 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham CPAP device - CPAP device with pressure delivered <1 cm H20
Description: Sham CPAP device used at night
Study NCT02948127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV LID cp ΔM2-2 Vaccine
Description: 10\^5 plaque-forming units (PFUs); administered as nose drops
Study NCT02948127 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as nose drops
Study NCT03367793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles - Clinically Derived
Description: Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.
Study NCT00899548 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: laboratory analysis
Study NCT03367793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles - Metric Technique #1 Derived
Description: Prescription spectacle lenses determined by metric-derived objective technique #1. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Visual Strehl ratio in the spatial domain (VSX). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #1 Derived.
Study NCT01393327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respiratory and exercise therapy
Description: Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
Study NCT03533985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Song of Kin
Description: Music therapists will assess meaningful song/theme (of choice/culture) and provide musical elements in a way that nurtures parents. They will then develop a simplified part of the theme into a soothing lullaby for their infants to be utilized directly by the parent/s and/or the music therapist to comfort, engage or sedate.
Study NCT03533985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gato box
Description: Depending on the time of intervention and need of the infant the music therapist will provide rhythmic entrainment that follows the heart rate or suck patterns of the infant
Study NCT03533985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ocean disc
Description: Depending on the time of intervention and needs of the infant the music therapist will provide a whoosh sound using the Remo Ocean disc. It will be entrained to the infant's respiratory rate.
Study NCT03533985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contingent singing
Description: Depending on the state of the infant, the music therapist will provide short segments of conversant prosody, to enhance quiet-alert, or stimulate relaxation/sleep
Study NCT03533985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tonal Vocal holding
Description: Music therapist will provide a vowel, long held tone, sung without vibrato
Study NCT03533985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muted shaker
Description: If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
Study NCT03367793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles - Metric Technique #2 Derived
Description: Prescription spectacle lenses determined by metric-derived objective technique #2. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Pupil Fraction tessellated (PFSt). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #2 Derived.
Study NCT02838771 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water drinking test
Description: Patient takes a sip of water about 60-70 ml. We assess: coughing, choking, voice changes.
Study NCT02838771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water drinking test
Description: Patient takes a sip of water about 60-70 ml. We assess: coughing, choking, voice changes.
Study NCT02838771 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dysphagia screening questionnaire
Description: Lithuanian version of the questionnaire consists of 16 questions. Interpretation of dysphagia screening questionnaire: advanced symptom - 2 points, moderate intensity symptom - 1 point, no symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points.
Study NCT01928212 — intervention group
Intervention type: DEVICE
Intervention: Optical coherence tomography
Study NCT02838771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dysphagia screening questionnaire
Description: Lithuanian version of the questionnaire consists of 16 questions. Interpretation of dysphagia screening questionnaire: advanced symptom - 2 points, moderate intensity symptom - 1 point, no symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points.
Study NCT02670031 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Description: For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
Study NCT02670031 — intervention group
Intervention type: OTHER
Intervention: Echocardiogram
Description: For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
Study NCT02670031 — intervention group
Intervention type: OTHER
Intervention: Electrocardiogram
Description: To examine specific function of the heart.
Study NCT02670031 — intervention group
Intervention type: DEVICE
Intervention: Ambulatory Blood Pressure Monitoring
Description: A 24-hour test.
Study NCT02670031 — intervention group
Intervention type: OTHER
Intervention: Retinal Photography (Optional)
Description: The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
Study NCT00044031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT Immunogen
Study NCT03426267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDN-037
Description: twice daily
Study NCT03426267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily
Study NCT04010825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention focused on the emotional dimension of the dyspnea
Description: Individual hypnosis sessions will be for 1 hour. Each hypnosis session will be standardized and evaluated using a script and an observation grid ( Visual Analogic Scale comfort, patient's hypnotic state...) written in collaboration with experts from Institut Milton Hyland Erickson Toulouse France (IMHETO).
Study NCT04068623 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood samples will be collected at 12 months after radiation therapy and at the time of first metastatic recurrence
Study NCT04271501 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB)
Description: Application of melanocytes (aka melanocyte-keratinocyte transplantation procedure or MKTP) to surgically prepared depigmented areas
Study NCT04271501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECELL 1:5 and Ultraviolet Lamp (UVB)
Description: Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
Study NCT04271501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECELL 1:10 and Ultraviolet Lamp (UVB)
Description: Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
Study NCT04271501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECELL 1:20 and Ultraviolet Lamp (UVB)
Description: Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
Study NCT02418221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DAOSiN®/ Placebo & ProvokAmin® Ingestion
Description: Proband is randomly assigned Daosin® or the Placebo before provocation with ProvokAmin®
Study NCT02418221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drawing blood, measuring BP & pulse
Description: Taking of a blood sample and recording of blood pressure \& pulse
Study NCT01708993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed and Reolysin (and safety run-in)
Description: Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
Study NCT01708993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks
Study NCT01708993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and Reolysin
Description: Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
Study NCT01708993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks
Study NCT00519038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pathways
Description: Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period with the aim to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. They are also developed by multi-professional teams
Study NCT00519038 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care is the current practice actually performed in the hospital
Study NCT02245906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Description: As a control, subjects are asked to consume 300 ml control drinks containing equal amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
Study NCT02245906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brazilian fruit peel flour
Description: In this study, subjects are asked to consume 300 ml beverage drinks contain certain amounts of Brazilian fruit peel flour. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
Study NCT02245906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Negative control drink
Description: As a negative control, subjects are asked to consume 300 ml control drinks without containing amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
Study NCT02102477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy/Surgery
Description: Radical prostatectomy with or without adjuvant or salvage radiotherapy
Study NCT02102477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy with adjuvant androgen deprivation therapy
Description: Radiotherapy with adjuvant androgen deprivation therapy
Study NCT00640887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin in combination with efavirenz
Description: Ia. arm 1a:~D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks);~Ib. arm 1b:~D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks);
Study NCT00640887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin in combination with nevirapine
Description: IIa. arm 2a:~D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks);~IIb. arm 2b :~D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks);
Study NCT00640887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin in combination with lopinavir/ritonavir
Description: IIIa. arm 3a :~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks);~IIIb. arm 3b:~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks).
Study NCT04431401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim rTMS
Description: The device is made in London,UK
Study NCT02850653 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCR : 16S ribosomal DNA and real-time targeted PCR